
ePROs in Oncology: Breaking Through Barriers for Better Drug Development and Higher Quality Care
Industry now leveraging reporting system to empower patients and improve research.
In the new paradigm of patient-centered research and care, the inclusion of patient reported outcomes (PROs) are central to evaluating new drugs, particularly in fields like oncology, where cancer patients’ diseases can be especially debilitating and affect their overall quality of life and life expectancy. Historically, trial participants battling cancer have also been burdened with reporting important toxicities and side effects directly to their providers. Incomplete reporting, patient bias and inadequate trial investigator communication can result in lack of information that could potentially improve drug labeling claims and inform researchers and regulators in the development and approval of new drugs,
To address these challenges, sponsors are now leveraging ePROs to create the opportunity to empower patients to self-report symptoms without bias. These tools can reduce cancer patient reporting burden and reluctance while capturing the best information on subjective symptoms. ePRO allows patients to easily report their conditions, symptoms, side effects, drug timing, directly from electronic devices.
Understanding adoption challenges in oncology
The standard paper-based practices that clinicians use to report patient toxicity symptoms and side effects in cancer trials are, by today’s standards,
Breaking down barriers for cancer patients with ePROs
PROs allow the possibility for patients to share with ease their symptoms, side effects, drug timing, etc., directly from technologies, such as smartphones and wearable devices. With patient centricity being at the core of most clinical trial designs today, ePROs ensure that participants have the best experience while providing clinicians visibility into the patient experience in order to deliver optimal care.This is because clinicians can directly monitor variables such as their patients’ tolerance, response, and symptoms, related to the disease itself or treatment effects. Capturing insights electronically enhances this process by enabling more frequent and holistic data reviews which can contribute to better clinical efficacy and improved outcomes while empowering patients. For example, the use of ePROs in studies of patients with advanced cancer
Creating a better future for cancer care
It is critical to continue to take advantage of technologies that promote quality care for cancer patients. ePROs offer a mutually beneficial solution for patients and providers for capturing the patient experience in a consistent, well-rounded, and simple way. Simultaneously, continuing to enable patients to self-report side effects and symptoms will help clinicians to holistically capture and report toxicities. The result will be better safety information about new therapies and enhanced future drug development overall. Looking forward, ePROs can become a cornerstone of evaluating cancer treatment. This technology will be essential to improve the experience of patients who do the important work of giving their time to clinical research to improve many lives beyond their own.
Melissa Mooney, Director, eCOA Solutions Engineering, IQVIA
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.